# US 2005/0038499 A1 · Methods for coating stents with DNA and expression of recombinant genes from DNA coated stents in vivo

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0038499 A1
- Document ID: US20050038499A1
- Status: Published application
- Kind: A1
- Application number: 10/946,785
- Filed: 2004-09-22
- Published: 2005-02-17
- Earliest claimed: 1997-06-27
- Inventors: Elizabeth Nabel; Gary Nabel; Zhi-yong Yang
- Web page: https://patentgrep.com/patent/US20050038499A1

## CPC

- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A61K 38/45: Transferases (2)
- A61K 38/50: acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61L 31/10: Macromolecular materials
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61F 2/82: Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents (stent-grafts for tubular structures of the body other than blood vessels A61F2/04; stent-grafts for blood vessels A61F2/07)
- A61L 2300/252: Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L 2300/258: Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
- A61L 2300/416: Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
- A61L 2300/606: Coatings
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)

## Abstract

The present invention describes DNA coated stents and methods of using the same to treat or prevent vascular diseases, such as restenosis.

## Claims

### Claim at position 1

1-20. Cancelled

### Claim 21

A method for expressing therapeutically useful amounts of recombinant genes in vivo, comprising the step of placing an implantable device into the vasculature of a patient, wherein the device comprises a biostable intravascular stent coated with a polymer matrix and DNA encoding a therapeutically useful protein, said DNA being uniformly-dispersed within said matrix.

### Claim 22 (depends on 21)

The method of claim 21, wherein the therapeutically useful protein is an antiplatelet agent, anticoagulant agent, antimitotic agent, antioxidant, antimetabolite agent, or anti-inflammatory agent.

### Claim 23 (depends on 21)

The method of claim 21, wherein the therapeutically useful protein inhibits the proliferation of cells.

### Claim 24 (depends on 21)

The method of claim 21, wherein the therapeutically useful protein is thymidine kinase, p16, p21, p27, p57, retinoblastoma or cytosine deaminase.

### Claim 25 (depends on 24)

The method of claim 24, wherein the therapeutically useful protein is thymidine kinase or cytosine deaminase.

### Claim 26

A method for treating or preventing a vascular disease, comprising the step of placing an implantable device into the vasculature of a patient, wherein the device comprises a biostable intravascular stent coated with a polymer matrix and DNA encoding a protein therapeutically useful for treating the vascular disease, said DNA being uniformly dispersed within said matrix.

### Claim 27 (depends on 26)

The method of claim 26, wherein the therapeutically useful protein is an antiplatelet agent, anticoagulant agent, antimitotic agent, antioxidant, antimetabolite agent, or anti-inflammatory agent.

### Claim 28 (depends on 26)

The method of claim 26, wherein the therapeutically useful protein inhibits the proliferation of cells.

### Claim 29 (depends on 26)

The method of claim 26, wherein the therapeutically useful protein is thymidine kinase, p16, p21, p27, p57, retinoblastoma or cytosine deaminase.

### Claim 30 (depends on 26)

The method of claim 26, wherein the therapeutically useful protein is thymidine kinase or cytosine deaminase.

### Claim 31 (depends on 26)

The method of claim 26, wherein the vascular disease is restenosis, atherosclerosis, coronary artery bypass graft stenosis or restenosis, arterio-venous fistula stenosis or restenosis, or peripheral artery stenosis or restenosis.

### Claim 32 (depends on 21)

The method of claim 21, wherein the DNA is naked DNA.

### Claim 33 (depends on 21)

The method of claim 21, wherein the DNA is incorporated into a vector.

### Claim 34 (depends on 33)

The method of claim 33, wherein the vector is selected from the group consisting of shuttle vectors, expression vectors, retroviral vectors, adenoviral vectors, adeno-associated vectors and liposomes.

### Claim 35 (depends on 21)

The method of claim 21, wherein the therapeutically useful protein is a fusion protein.

### Claim 36 (depends on 21)

The method of claim 21, wherein the DNA comprises a sm22α promoter operatively linked to the DNA encoding the therapeutically useful protein.

### Claim 37 (depends on 26)

The method of claim 26, wherein the DNA is naked DNA.

### Claim 38 (depends on 26)

The method of claim 26, wherein the DNA is incorporated into a vector.

### Claim 39 (depends on 38)

The method of claim 38, wherein the vector is selected from the group consisting of shuttle vectors, expression vectors, retroviral vectors, adenoviral vectors, adeno-associated vectors and liposomes.

### Claim 40 (depends on 26)

The method of claim 26, wherein the therapeutically useful protein is a fusion protein.

### Claim 41 (depends on 26)

The method of claim 26, wherein the DNA comprises a sm22α promoter operatively linked to the DNA encoding the therapeutically useful protein.

### Claim 42 (depends on 21)

The method of claim 21, wherein the polymer matrix is formed from an aqueous suspension of DNA and liquid monomeric matrix.

### Claim 43 (depends on 21)

The method of claim 21, wherein the stent is a polymeric or metallic stent.

### Claim 44 (depends on 21)

The method of claim 21, wherein the stent is stainless steel.

### Claim 45 (depends on 21)

The method of claim 21, wherein the stent is coated with about 50 μg to about 5 mg of DNA.

### Claim 46 (depends on 21)

The method of claim 21, wherein the polymer matrix comprises fibrin.

### Claim 47 (depends on 21)

The method of claim 21, wherein the stent is a polymeric stent comprising poly(ethylene terephthalate), polyacetal, poly(lactic acid), and poly(ethylene oxide)/poly(butylene terephthalate) copolymer.

### Claim 48 (depends on 26)

The method of claim 26, wherein the polymer matrix is formed from an aqueous suspension of DNA and liquid monomeric matrix.

### Claim 49 (depends on 26)

The method of claim 26, wherein the stent is a polymeric or metallic stent.

### Claim 50 (depends on 26)

The method of claim 26, wherein the stent is stainless steel.

### Claim 51 (depends on 26)

The method of claim 26, wherein the stent is coated with about 50 μg to about 5 mg of DNA.

### Claim 52 (depends on 26)

The method of claim 26, wherein the polymer matrix comprises fibrin.

### Claim 53 (depends on 26)

The method of claim 26, wherein the stent is a polymeric stent comprising poly(ethylene terephthalate), polyacetal, poly(lactic acid), and poly(ethylene oxide)/poly(butylene terephthalate) copolymer.

### Claim 54

A method for expressing therapeutically useful amounts of recombinant genes in vivo, comprising the step of placing an implantable device into the vasculature of a patient, wherein the device comprises a biostable intravascular stent coated with a polymer matrix and DNA encoding a therapeutically useful protein, said DNA being in contact with said matrix.

### Claim 55 (depends on 54)

The method of claim 54, wherein the therapeutically useful protein inhibits the proliferation of cells.

### Claim 56 (depends on 54)

The method of claim 54, wherein the therapeutically useful protein is thymidine kinase, p16, p21, p27, p57, retinoblastoma, protein or cytosine deaminase.
